» Articles » PMID: 10831593

Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator As Substrates

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2000 Jun 1
PMID 10831593
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

Membrane-type serine protease 1 (MT-SP1) was recently cloned, and we now report its biochemical characterization. MT-SP1 is predicted to be a type II transmembrane protein with an extracellular protease domain. This localization was experimentally verified using immunofluorescent microscopy and a cell-surface biotinylation technique. The substrate specificity of MT-SP1 was determined using a positional scanning-synthetic combinatorial library and substrate phage techniques. The preferred cleavage sequences were found to be (P4-(Arg/Lys)P3-(X)P2-(Ser)P1-(Arg)P1'-(Ala)) and (P4-(X)P3-(Arg/Lys)P2-(Ser)P1(Arg) P1'(Ala)), where X is a non-basic amino acid. Protease-activated receptor 2 (PAR2) and single-chain urokinase-type plasminogen activator are proteins that are localized to the extracellular surface and contain the preferred MT-SP1 cleavage sequence. The ability of MT-SP1 to activate PARs was assessed by exposing PAR-expressing Xenopus oocytes to the soluble MT-SP1 protease domain. The latter triggered calcium signaling in PAR2-expressing oocytes at 10 nm but failed to trigger calcium signaling in oocytes expressing PAR1, PAR3, or PAR4 at 100 nm. Single-chain urokinase-type plasminogen activator was activated using catalytic amounts of MT-SP1 (1 nm), but plasminogen was not cleaved under similar conditions. The membrane localization of MT-SP1 and its affinity for these key extracellular substrates suggests a role of the proteolytic activity in regulatory events.

Citing Articles

Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency.

Joushomme A, Desilets A, Champagne W, Hassanzadeh M, Lemieux G, Gravel-Trudeau A J Enzyme Inhib Med Chem. 2025; 40(1):2466841.

PMID: 39976239 PMC: 11843629. DOI: 10.1080/14756366.2025.2466841.


Endothelial protease-activated receptor 4: impotent or important?.

Rajala R, Griffin C Front Cardiovasc Med. 2025; 12:1541879.

PMID: 39935714 PMC: 11810968. DOI: 10.3389/fcvm.2025.1541879.


Development of ketobenzothiazole-based peptidomimetic TMPRSS13 inhibitors with low nanomolar potency.

Joushomme A, Desilets A, Champagne W, Hassanzadeh M, Lemieux G, Gravel-Trudeau A bioRxiv. 2024; .

PMID: 39257753 PMC: 11383682. DOI: 10.1101/2024.08.28.609965.


Use of protease substrate specificity screening in the rational design of selective protease inhibitors with unnatural amino acids: Application to HGFA, matriptase, and hepsin.

Mahoney M, Helander J, Kooner A, Norman M, Damalanka V, De Bona P Protein Sci. 2024; 33(8):e5110.

PMID: 39073183 PMC: 11284329. DOI: 10.1002/pro.5110.


Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.

Padin J, Perez-Ortiz J, Redondo-Calvo F Int J Mol Sci. 2024; 25(13).

PMID: 39000315 PMC: 11241800. DOI: 10.3390/ijms25137209.